IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) shares hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $26.56 and last traded at $26.9810, with a volume of 72,622 shares. The stock had previously closed at $27.40.
Wall Street Analyst Weigh In
IDYA has been the subject of several research reports. Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 1st. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 22nd. Royal Bank Of Canada reiterated an “outperform” rating and set a $45.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday. Wedbush raised their price target on IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Finally, Citigroup upped their price objective on IDEAYA Biosciences from $65.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.55.
View Our Latest Report on IDYA
IDEAYA Biosciences Stock Down 1.2%
The business has a fifty day moving average of $34.59 and a two-hundred day moving average of $33.79.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.04). The business had revenue of $10.24 million during the quarter, compared to analysts’ expectations of $7.58 million. IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. IDEAYA Biosciences’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.33 earnings per share. Analysts expect that IDEAYA Biosciences, Inc. will post -4.68 earnings per share for the current year.
Insider Activity at IDEAYA Biosciences
In related news, CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the completion of the sale, the chief executive officer owned 690,695 shares in the company, valued at approximately $25,838,899.95. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is currently owned by insiders.
Institutional Investors Weigh In On IDEAYA Biosciences
Several hedge funds have recently modified their holdings of IDYA. BlackRock Inc. acquired a new position in shares of IDEAYA Biosciences in the second quarter valued at approximately $331,452,000. Jupiter Topco LLC purchased a new stake in IDEAYA Biosciences in the 2nd quarter worth approximately $319,728,000. Janus Henderson Group PLC grew its stake in IDEAYA Biosciences by 1.1% in the 1st quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after acquiring an additional 78,797 shares during the period. Goldman Sachs Group Inc. grew its stake in IDEAYA Biosciences by 18.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company’s stock worth $55,863,000 after acquiring an additional 222,383 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in IDEAYA Biosciences by 42.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,333,478 shares of the company’s stock valued at $44,418,000 after acquiring an additional 394,621 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.
Further Reading
- Five stocks we like better than IDEAYA Biosciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
